| Hay, Mohammad M Abdul |
NCT03258931: Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML |
|
|
| Recruiting | 3 | 510 | US | Crenolanib, Crenolanib besylate, Midostaurin, Cytarabine, Duanorubicin | Arog Pharmaceuticals, Inc. | Newly Diagnosed FLT3 Mutated AML | 11/22 | 11/24 | | |
| Recruiting | 2a | 108 | US | BP1001 in combination with Ventoclax plus decitabine, Liposomal Grb-2, L-Grb-2, BP1001 plus decitabine | Bio-Path Holdings, Inc. | Acute Myeloid Leukemia (AML) | 12/24 | 12/24 | | |
| Completed | 2 | 39 | US | MBG453, sabatolimab, Azacitidine, Decitabine, INQOVI (oral decitabine) | Novartis Pharmaceuticals | Myelodysplastic Syndrome (MDS) | 09/23 | 09/24 | | |
| Terminated | 1/2 | 40 | US | ZN-d5 ZN-c3, Study Drug, ZN-c3 | K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. | Acute Myeloid Leukemia (AML) | 07/24 | 07/24 | | |
|
NCT03433781: A Phase Ib Study Evaluating the Safety and Tolerability of Vitamin C in Patients With Intermediate or High Risk Myelodysplastic Syndrome With TET2 Mutations |
|
|
| Completed | 1/2 | 4 | US | Vitamin C, ascorbic acid, ascorbate | NYU Langone Health, Perlmutter Cancer Center | Myelodysplastic Syndromes | 11/22 | 05/23 | | |
CLN-049-001, NCT05143996: CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) |
|
|
| Recruiting | 1 | 60 | US | CLN-049 | Cullinan Oncology Inc. | Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) | 08/25 | 11/25 | | |
NCT04509765: A Phase II Single-arm Study of Total Body Irradiation With Linac Based VMAT and IGRT |
|
|
| Active, not recruiting | N/A | 35 | US | Linac Based VMAT TBI | NYU Langone Health | Hematologic Malignancy | 09/24 | 09/24 | | |
